Press Releases

Press Releases

DENVER – A new test could reliably detect early increases in prostate specific antigen (PSA) levels – a biomarker commonly used to measure the recurrence of prostate cancer – in men who have undergone prostate cancer-treating surgery. Earlier detection of these rising levels would allow men with…
CAMBRIDGE, MA – July 21, 2011 – Quanterix Corporation, an in vitro diagnostics (IVD) company providing life science researchers and IVD labs single molecule technology with unprecedented sensitivity and precision, announced that the analytical performance of AccuPSA™, a fifth–generation digital…
CAMBRIDGE, MA – January 5, 2012 – Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, announced today a strategic investment and technology development agreement with In–Q–Tel (IQT), the…
LEXINGTON, Mass., July 30, 2013 – Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today unveiled its Single Molecule Array (Simoa) technology at the 2013 AACC Annual Meeting in Houston, Texas,…
Lexington, Mass. – March 14, 2014 – Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that JAMA Neurology has published a ground-breaking study in which its Simoa (single molecule…
LEXINGTON, MA – February 4, 2015 Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that they will be recognized as a SLAS Innovation Award finalist.
LEXINGTON, MA – June 9, 2015 Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced commercial availability of its multiplex panels, providing users with the ability to develop their own…
LEXINGTON, MA – October 20, 2015 Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that it is hosting its second bi-annual conference, entitled, “Proteins Powering NexGen Healthcare…
February 9, 2016
Quanterix announces that Analytical Chemistry, a leading peer-reviewed scientific journal, has published a truly groundbreaking new study authored by Dr. David Walt of Tufts University that prominently features Quanterix’s Single Molecule Array Detection technology, Simoa.     
August 1, 2016
Quanterix announces a license agreement for research use with Banyan Biomarkers, a pioneering company in the development of biomarkers for traumatic brain injury (TBI).